SK53597A3 - A storage stable water solution for infusion containing a thrombin inhibitor - Google Patents

A storage stable water solution for infusion containing a thrombin inhibitor Download PDF

Info

Publication number: SK53597A3
Authority: SK; Slovakia
Prior art keywords: solution; hooc; nag; pic; cha
Prior art date: 1994-11-08

Application number

SK535-97A

Other languages

English (en)

Slovak (sk)

Inventor

Ulla Stjernfelt

Mats Sundgren

Original Assignee

Astra Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-11-08

Filing date

1995-10-19

Publication date

1998-07-08

1995-10-19 Application filed by Astra Ab filed Critical Astra Ab

1998-07-08 Publication of SK53597A3 publication Critical patent/SK53597A3/sk

Links

229940122388 Thrombin inhibitor Drugs 0.000 title claims abstract description 22
239000003868 thrombin inhibitor Substances 0.000 title claims abstract description 22
238000003860 storage Methods 0.000 title claims abstract description 16
101000712605 Theromyzon tessulatum Theromin Proteins 0.000 title claims abstract description 15
238000001802 infusion Methods 0.000 title claims abstract description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims description 13
239000012458 free base Substances 0.000 claims abstract description 19
150000003839 salts Chemical class 0.000 claims abstract description 9
238000000034 method Methods 0.000 claims abstract description 8
238000002360 preparation method Methods 0.000 claims abstract description 3
239000000243 solution Substances 0.000 claims description 38
150000001875 compounds Chemical class 0.000 claims description 17
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 16
239000007864 aqueous solution Substances 0.000 claims description 14
239000004480 active ingredient Substances 0.000 claims description 4
150000007522 mineralic acids Chemical class 0.000 claims description 3
230000000087 stabilizing effect Effects 0.000 claims description 3
150000007524 organic acids Chemical class 0.000 claims description 2
239000002253 acid Substances 0.000 claims 3
229910052500 inorganic mineral Inorganic materials 0.000 claims 3
108090000190 Thrombin Proteins 0.000 claims 2
239000003112 inhibitor Substances 0.000 claims 2
229960004072 thrombin Drugs 0.000 claims 2
230000002401 inhibitory effect Effects 0.000 claims 1
230000005764 inhibitory process Effects 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 17
238000009472 formulation Methods 0.000 abstract description 3
230000015556 catabolic process Effects 0.000 description 23
238000006731 degradation reaction Methods 0.000 description 23
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
239000007853 buffer solution Substances 0.000 description 13
108090000765 processed proteins & peptides Proteins 0.000 description 9
239000011780 sodium chloride Substances 0.000 description 9
239000008351 acetate buffer Substances 0.000 description 7
230000007423 decrease Effects 0.000 description 6
102000004196 processed proteins & peptides Human genes 0.000 description 4
239000000654 additive Substances 0.000 description 3
239000011521 glass Substances 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000007911 parenteral administration Methods 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
230000002378 acidificating effect Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
DKAGJZJALZXOOV-UHFFFAOYSA-N hydrate;hydrochloride Chemical compound O.Cl DKAGJZJALZXOOV-UHFFFAOYSA-N 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
206010020608 Hypercoagulation Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
WHKBVSXUVMMZBI-UHFFFAOYSA-M [OH-].[Na+].Br.Br Chemical compound [OH-].[Na+].Br.Br WHKBVSXUVMMZBI-UHFFFAOYSA-M 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
239000003708 ampul Substances 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000003027 hypercoagulation Effects 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000013112 stability test Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000000825 ultraviolet detection Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Epidemiology (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Diabetes (AREA)
Hematology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

SK535-97A 1994-11-08 1995-10-19 A storage stable water solution for infusion containing a thrombin inhibitor SK53597A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9403831A SE504185C2 (sv)	1994-11-08	1994-11-08	Lagringsstabil vattenlösning för infusion av trombininhibitorer
PCT/SE1995/001228 WO1996014084A1 (en)	1994-11-08	1995-10-19	A storage stable water solution for infusion containing a thrombin inhibitor

Publications (1)

Publication Number	Publication Date
SK53597A3 true SK53597A3 (en)	1998-07-08

Family

ID=20395892

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK535-97A SK53597A3 (en)	1994-11-08	1995-10-19	A storage stable water solution for infusion containing a thrombin inhibitor

Country Status (31)

Country	Link
US (1)	US5830865A (cs)
EP (1)	EP0789585B1 (cs)
JP (1)	JPH10508598A (cs)
KR (1)	KR100416677B1 (cs)
CN (1)	CN1090508C (cs)
AT (1)	ATE205399T1 (cs)
AU (1)	AU695719B2 (cs)
BR (1)	BR9509634A (cs)
CA (1)	CA2203396A1 (cs)
CZ (1)	CZ287256B6 (cs)
DE (1)	DE69522702T2 (cs)
DK (1)	DK0789585T3 (cs)
EE (1)	EE9700218A (cs)
ES (1)	ES2163528T3 (cs)
FI (1)	FI971949A0 (cs)
HU (1)	HU217073B (cs)
IL (1)	IL115879A (cs)
IS (1)	IS4468A (cs)
MX (1)	MX9703339A (cs)
MY (1)	MY112593A (cs)
NO (1)	NO322048B1 (cs)
NZ (1)	NZ295492A (cs)
PL (1)	PL320342A1 (cs)
PT (1)	PT789585E (cs)
RU (1)	RU2164803C2 (cs)
SE (1)	SE504185C2 (cs)
SK (1)	SK53597A3 (cs)
TR (1)	TR199501391A2 (cs)
TW (1)	TW407057B (cs)
WO (1)	WO1996014084A1 (cs)
ZA (1)	ZA959377B (cs)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6984627B1 (en) *	1993-06-03	2006-01-10	Astrazeneca Ab	Peptide derivatives
SE9301916D0 (sv) *	1993-06-03	1993-06-03	Ab Astra	New peptides derivatives
TWI238827B (en) *	1995-12-21	2005-09-01	Astrazeneca Ab	Prodrugs of thrombin inhibitors
SE9802974D0 (sv) *	1998-09-03	1998-09-03	Astra Ab	New crystalline forms
US6462021B1 (en)	2000-11-06	2002-10-08	Astrazeneca Ab	Use of low molecular weight thrombin inhibitor
AU2003302238A1 (en)	2002-12-03	2004-06-23	Axys Pharmaceuticals, Inc.	2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors
US7345093B2 (en) *	2004-04-27	2008-03-18	Formatech, Inc.	Methods of enhancing solubility of compounds
US20110070294A1 (en) *	2009-09-23	2011-03-24	Javeri Indu	Methods for the Administration of Drugs Using Liposomes
CA2781527C (en) *	2009-09-23	2017-10-24	Indu Javeri	Methods for the preparation of liposomes
US10143652B2 (en)	2009-09-23	2018-12-04	Curirx Inc.	Methods for the preparation of liposomes
MX2021008557A (es) *	2021-01-13	2021-11-17	Grupo Ion Biotech S A P I De C V	Sistema de suministro de ionoforos quimicos de membrana celular sintetica que comprende composiciones de ligandos hexa-acuaticos.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2096415C1 (ru) *	1991-09-30	1997-11-20	Дзе Дюпон Мерк Фармасьютикал Компани	Циклические пептиды или их фармацевтически приемлемые соли, фармацевтическая композиция
SE9103612D0 (sv) *	1991-12-04	1991-12-04	Astra Ab	New peptide derivatives
US5466131A (en) *	1994-03-22	1995-11-14	Micropump Corporation	Multiple-chamber gear pump with hydraulically connected chambers

1994
- 1994-11-08 SE SE9403831A patent/SE504185C2/sv not_active IP Right Cessation
1995
- 1995-10-04 TW TW084110363A patent/TW407057B/zh not_active IP Right Cessation
- 1995-10-19 PT PT95938085T patent/PT789585E/pt unknown
- 1995-10-19 EE EE9700218A patent/EE9700218A/xx unknown
- 1995-10-19 DE DE69522702T patent/DE69522702T2/de not_active Expired - Fee Related
- 1995-10-19 PL PL95320342A patent/PL320342A1/xx unknown
- 1995-10-19 SK SK535-97A patent/SK53597A3/sk unknown
- 1995-10-19 ES ES95938085T patent/ES2163528T3/es not_active Expired - Lifetime
- 1995-10-19 DK DK95938085T patent/DK0789585T3/da active
- 1995-10-19 MX MX9703339A patent/MX9703339A/es not_active IP Right Cessation
- 1995-10-19 KR KR1019970703043A patent/KR100416677B1/ko not_active Expired - Fee Related
- 1995-10-19 CZ CZ19971294A patent/CZ287256B6/cs not_active IP Right Cessation
- 1995-10-19 AT AT95938085T patent/ATE205399T1/de not_active IP Right Cessation
- 1995-10-19 HU HU9800400A patent/HU217073B/hu not_active IP Right Cessation
- 1995-10-19 NZ NZ295492A patent/NZ295492A/en unknown
- 1995-10-19 BR BR9509634A patent/BR9509634A/pt active Search and Examination
- 1995-10-19 CA CA002203396A patent/CA2203396A1/en not_active Abandoned
- 1995-10-19 CN CN95196108A patent/CN1090508C/zh not_active Expired - Fee Related
- 1995-10-19 JP JP8515235A patent/JPH10508598A/ja not_active Ceased
- 1995-10-19 AU AU38846/95A patent/AU695719B2/en not_active Ceased
- 1995-10-19 EP EP95938085A patent/EP0789585B1/en not_active Expired - Lifetime
- 1995-10-19 US US08/557,189 patent/US5830865A/en not_active Expired - Fee Related
- 1995-10-19 RU RU97108965/14A patent/RU2164803C2/ru active
- 1995-10-19 WO PCT/SE1995/001228 patent/WO1996014084A1/en not_active Ceased
- 1995-10-19 FI FI971949A patent/FI971949A0/fi not_active Application Discontinuation
- 1995-10-26 MY MYPI95003226A patent/MY112593A/en unknown
- 1995-11-06 IL IL11587995A patent/IL115879A/en not_active IP Right Cessation
- 1995-11-06 ZA ZA959377A patent/ZA959377B/xx unknown
- 1995-11-08 TR TR95/01391A patent/TR199501391A2/xx unknown
1997
- 1997-04-21 IS IS4468A patent/IS4468A/is unknown
- 1997-05-05 NO NO19972065A patent/NO322048B1/no unknown

Also Published As

Publication number	Publication date
SE9403831D0 (sv)	1994-11-08
NO322048B1 (no)	2006-08-07
RU2164803C2 (ru)	2001-04-10
CN1162921A (zh)	1997-10-22
MX9703339A (es)	1997-07-31
DE69522702D1 (de)	2001-10-18
AU3884695A (en)	1996-05-31
NO972065D0 (no)	1997-05-05
PT789585E (pt)	2002-01-30
NZ295492A (en)	1998-06-26
TR199501391A2 (tr)	1996-06-21
KR100416677B1 (ko)	2004-06-16
TW407057B (en)	2000-10-01
FI971949A7 (fi)	1997-05-07
AU695719B2 (en)	1998-08-20
ZA959377B (en)	1996-05-08
EP0789585A1 (en)	1997-08-20
CN1090508C (zh)	2002-09-11
EE9700218A (et)	1998-02-16
FI971949L (fi)	1997-05-07
IS4468A (is)	1997-04-21
KR970706844A (ko)	1997-12-01
US5830865A (en)	1998-11-03
CA2203396A1 (en)	1996-05-17
EP0789585B1 (en)	2001-09-12
IL115879A0 (en)	1996-01-31
HU217073B (hu)	1999-11-29
NO972065L (no)	1997-05-05
WO1996014084A1 (en)	1996-05-17
IL115879A (en)	2001-08-08
HUT77560A (hu)	1998-06-29
CZ287256B6 (en)	2000-10-11
MY112593A (en)	2001-07-31
ES2163528T3 (es)	2002-02-01
JPH10508598A (ja)	1998-08-25
SE9403831L (sv)	1996-05-09
CZ129497A3 (cs)	1998-02-18
DE69522702T2 (de)	2002-07-11
ATE205399T1 (de)	2001-09-15
PL320342A1 (en)	1997-09-29
FI971949A0 (fi)	1997-05-07
BR9509634A (pt)	1998-01-06
SE504185C2 (sv)	1996-12-02
DK0789585T3 (da)	2001-11-12

Publication	Publication Date	Title
US10406226B2 (en)	2019-09-10	Method of manufacturing VEGF antagonist fusion proteins
KR920003331B1 (ko)	1992-04-27	활성성분으로 스페르구알린(Spergualin)을 함유하는 주사제 조성물과 그 제조방법.
US7803762B1 (en)	2010-09-28	Ready-to-use bivalirudin compositions
SK47298A3 (en)	1998-11-04	Stable pharmaceutical forms of administration containing parathormone
SK53597A3 (en)	1998-07-08	A storage stable water solution for infusion containing a thrombin inhibitor
EA039003B1 (ru)	2021-11-19	Фармацевтическая композиция для парентерального введения, содержащая карглумовую кислоту
EP0298192B1 (en)	1991-07-24	Stable, injectable solutions of vincristine salts
BRPI0214412B1 (pt)	2016-01-05	solução aquosa contendo ácido glicônico, manitol e tween 80 para injeção de antagonista de hormônio liberador de gonadotrofina (lhrh), bem como seu processo de preparação
US6020359A (en)	2000-02-01	Pharmaceutical composition
BG63621B1 (bg)	2002-07-31	Стабилизирани фармацевтични състави на база хинупристин и далфопристин и тяхното получаване
NZ231094A (en)	1991-12-23	Pharmaceutical composition containing 1-diphenylmethyl-4-((2-(4-methylphenyl)-5-methyl-1h-imidazol-4-yl)methyl)-piperazine
EP1371369A1 (en)	2003-12-17	Compositions comprising remifentanil
HK1184680B (en)	2018-03-16	Vegf antagonist formulations